Antiplatelet Treatment Preferences of a Group of Cardiologists from Türkiye: A Survey Research Study.

Özge Çetinarslan, Mustafa Yenerçağ, Mehdi Zoghi, Asım Oktay Ergene
{"title":"Antiplatelet Treatment Preferences of a Group of Cardiologists from Türkiye: A Survey Research Study.","authors":"Özge Çetinarslan, Mustafa Yenerçağ, Mehdi Zoghi, Asım Oktay Ergene","doi":"10.5543/tkda.2023.54778","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex decision. This survey aims to explore the preferences for antiplatelet therapy and the daily routine regarding DAPT duration in coronary artery disease among a group of cardiologists in Türkiye.</p><p><strong>Method: </strong>Using an online questionnaire with 38 questions, the preferences of 314 cardiologists were collected. Qualitative descriptive characteristics of the answers received from the participants were examined.</p><p><strong>Results: </strong>Participating cardiologists mostly worked in training and research hospitals (51.59%) and university hospitals (21.66%). Participants primarily favored ticagrelor in patients undergoing PCI with a diagnosis of STEMI and NSTE-ACS (69.75% and 55.73% respectively). Clopidogrel was the most preferred P2Y12 treatment in patients with chronic coronary syndrome (CCS) after PCI (94.90%). Pre-treatment with a loading dose of a P2Y12 receptor inhibitor was administered to 57.01% of patients with NSTE-ACS, irrespective of the planned treatment strategy. In NSTE-ACS patients with low bleeding risk treated with PCI, 83.12% of participants recommended DAPT for 12 months and 14.65% for >12 months. In high-bleeding-risk NSTE-ACS patients treated with PCI, DAPT durations of six months (74.52%), three months (19.75%), and one month (5.73%) were chosen. Among CCS patients treated with PCI without an increased risk of bleeding, 12 months of DAPT was preferred by 68.15% of participants. Most participants (70.70%) were switching to a more potent P2Y12 receptor inhibitor therapy in emergency department clopidogrel-loaded patients with ACS.</p><p><strong>Conclusion: </strong>The aim of this survey to capture a snapshot of the preferences of a group of cardiologists in Türkiye regarding DAPT treatment and duration. The responses were both in accordance and in conflict with the current guidelines.</p>","PeriodicalId":94261,"journal":{"name":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","volume":"52 2","pages":"116-124"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5543/tkda.2023.54778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Deciding on the optimal duration of dual antiplatelet treatment (DAPT) remains a complex decision. This survey aims to explore the preferences for antiplatelet therapy and the daily routine regarding DAPT duration in coronary artery disease among a group of cardiologists in Türkiye.

Method: Using an online questionnaire with 38 questions, the preferences of 314 cardiologists were collected. Qualitative descriptive characteristics of the answers received from the participants were examined.

Results: Participating cardiologists mostly worked in training and research hospitals (51.59%) and university hospitals (21.66%). Participants primarily favored ticagrelor in patients undergoing PCI with a diagnosis of STEMI and NSTE-ACS (69.75% and 55.73% respectively). Clopidogrel was the most preferred P2Y12 treatment in patients with chronic coronary syndrome (CCS) after PCI (94.90%). Pre-treatment with a loading dose of a P2Y12 receptor inhibitor was administered to 57.01% of patients with NSTE-ACS, irrespective of the planned treatment strategy. In NSTE-ACS patients with low bleeding risk treated with PCI, 83.12% of participants recommended DAPT for 12 months and 14.65% for >12 months. In high-bleeding-risk NSTE-ACS patients treated with PCI, DAPT durations of six months (74.52%), three months (19.75%), and one month (5.73%) were chosen. Among CCS patients treated with PCI without an increased risk of bleeding, 12 months of DAPT was preferred by 68.15% of participants. Most participants (70.70%) were switching to a more potent P2Y12 receptor inhibitor therapy in emergency department clopidogrel-loaded patients with ACS.

Conclusion: The aim of this survey to capture a snapshot of the preferences of a group of cardiologists in Türkiye regarding DAPT treatment and duration. The responses were both in accordance and in conflict with the current guidelines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
图尔基耶心脏病专家的抗血小板治疗偏好:一项调查研究。
目的:决定双联抗血小板治疗 (DAPT) 的最佳持续时间仍是一项复杂的决策。本调查旨在了解土耳其心脏病专家对冠心病抗血小板治疗的偏好以及有关 DAPT 持续时间的日常生活:方法:通过一份包含 38 个问题的在线问卷,收集了 314 名心脏病专家的偏好。方法:使用包含 38 个问题的在线问卷收集了 314 名心脏病专家的偏好,并研究了从参与者收到的答案的定性描述特征:参与调查的心脏病专家大多在培训与研究医院(51.59%)和大学医院(21.66%)工作。对于诊断为 STEMI 和 NSTE-ACS 的接受 PCI 治疗的患者,与会者主要倾向于使用替卡格雷(分别占 69.75% 和 55.73%)。氯吡格雷是接受 PCI 治疗的慢性冠状动脉综合征(CCS)患者最青睐的 P2Y12 治疗方法(94.90%)。57.01%的 NSTE-ACS 患者接受了负荷剂量 P2Y12 受体抑制剂的预处理,无论计划采用哪种治疗策略。在接受 PCI 治疗的低出血风险 NSTE-ACS 患者中,83.12% 的参与者建议使用 12 个月的 DAPT,14.65% 的患者建议使用 12 个月以上的 DAPT。在接受 PCI 治疗的高出血风险 NSTE-ACS 患者中,选择 DAPT 的时间分别为 6 个月(74.52%)、3 个月(19.75%)和 1 个月(5.73%)。在接受 PCI 治疗且出血风险未增加的 CCS 患者中,68.15% 的参与者选择 12 个月的 DAPT。大多数参与者(70.70%)认为,急诊科氯吡格雷负荷过重的 ACS 患者应改用更强效的 P2Y12 受体抑制剂治疗:本次调查旨在了解土耳其心脏病专家对 DAPT 治疗和持续时间的偏好。调查结果与现行指南既有一致之处,也有冲突之处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acute Humoral Rejection 12 Days Post-Heart Transplantation with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Expression in Myocardial Tissue: A Clinical Case. Assessment of Non-Vitamin K Antagonist Oral Anticoagulant Dosing Patterns in Turkish Patients with Non-Valvular Atrial Fibrillation: A Multicenter, Cross-Sectional Study with Insights from the ASPECT-NOAC Study. Clinical Management Strategies of Cardiologists in Heart Failure with Reduced Ejection Fraction in Türkiye. Clinical Significance of Coronary Artery Tortuosity in Chronic Coronary Syndrome and Stable Angina: Insights from Gensini Scores. [News and Comments from Cardiology].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1